Top broker says buy ResMed and this ASX 200 share

Ord Minnett was impressed with their quarterly updates from last month.

| More on:
Happy shareholders clap and smile as they listen to a company earnings report.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A number of companies have released their quarterly updates in recent weeks.

Analysts at Ord Minnett have been running the rule over these updates and have picked out two ASX 200 shares that impressed enough to be rated as buys.

Here's what the broker is saying about them:

ResMed Inc. (ASX: RMD)

The first ASX 200 share that impressed is ResMed. It is a developer, manufacturer, distributor, and marketer of medical device and cloud-based software applications targeting the management of sleep apnoea.

Ord Minnett described ResMed's result as "strong" and has bumped its earnings estimates higher to reflect this and its positive outlook. It said:

The company delivered a strong September quarter result, with 11% revenue growth translating to 35% earnings per share growth. Revenues were 3% ahead of consensus due to higher rates of flow generator growth. ‍ The gross margin of 59.2% aligned with expectations, while operating expenses were slightly ahead of forecasts. ‍ Net operating cash flow increased by 14% compared to the previous corresponding period, despite higher inventory due to rebalancing sea versus air freight. Net debt fell, while the value of share buyback program was boosted.

ResMed upped it FY25 EPS guidance thanks to jump higher flow generator revenues. Revenue growth for the current quarter is forecast at 10%. We forecast the company will be able to generate annualised EPS growth of 13% for the next few years, which justifies its current trading multiples. We ticked our price target up from $39.25 to $40.05 following the quarterly.

Whitehaven Coal Ltd (ASX: WHC)

As well as ResMed shares, Ord Minnett is tipping Whitehaven Coal as an ASX 200 share to buy following the recent flurry of quarterly updates.

It develops and operates metallurgical and thermal coal mines in New South Wales and Queensland. ‍

Much like ResMed, the broker highlights that Whitehaven Coal delivered a solid quarterly update last month. It said:

The company had a solid September quarter of production and sales, with all mines delivering as planned or better. Group performance in Q1FY25 included managed run-of-mine production of 9.7Mt, and total equity sales of 6.4Mt. Net debt was $1.2 billion. ‍ Queensland operations achieved strong production and productivity improvements at Blackwater and Daunia, with run-of-mine (ROM)production up 11% and sales up 13%. Average coal price increased to $259/t. ‍

New South Wales saw improved Narrabri production and focused on overburden removal. Run-of-mine production was down 12%, with equity sales down 16%. Average coal price was $211/t. ‍ Run-of-mine coal production is expected to increase in the second half of FY25. Global metallurgical coal production shortfalls and increased Indian demand are expected to drive prices higher, which will benefit Whitehaven. ‍

In light of this, it has put a buy rating and $9.00 price target on its shares.

Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Man putting in a coin in a coin jar with piles of coins next to it.
Broker Notes

Two ASX penny stocks Bell Potter thinks are worth watching in 2026

Bell Potter is tipping upside on these penny stocks.

Read more »

A financial expert or broker looks worried as he checks out a graph showing market volatility.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to buy these shares.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Broker Notes

Why Bell Potter just upgraded this ASX All Ords share to a buy rating

The broker has turned bullish on this growing company. Here's what you need to know.

Read more »

A female broker in a red jacket whispers in the ear of a man who has a surprised look on his face as she explains which two ASX 200 shares should do well in today's volatile climate
Broker Notes

Bell Potter says these ASX shares are best buys in January

The broker has good things to say about these shares.

Read more »

Broker written in white with a man drawing a yellow underline.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A group of people push and shove through the doors of a store, trying to beat the crowd.
Broker Notes

2 ASX shares highly recommended to buy: Experts

Are these two stocks the best buys on the ASX?

Read more »

Smiling couple sitting on a couch with laptops fist pump each other.
Broker Notes

These ASX 200 shares could rise 20% to 55%

Brokers have good things to say about these shares.

Read more »

A little girl is about to launch down the slide with a blue sky and white clouds in the sky behind her.
Broker Notes

BHP vs. Fortescue shares: Goldman Sachs says 1 will rip and 1 will dip

Top broker Goldman Sachs upgraded its 12-month share price forecasts for BHP and Fortescue shares this week.

Read more »